A significantly increased prevalence of CDKN2A mutation (15% vs 0.1%) was seen in the CR-mut astrocytoma group which was not observed in the GBM (5% vs 3%) comparison. Here, CDKN2A is linked to astrocytoma (excluding glioblastoma).